SYMBIOTEC PHARMALAB LIMITED
ClosedPharmaceuticals · Mainboard IPO · INE899I01028
Price band
₹938 – ₹988
Lot size
15 shares
Min. investment
₹14,820
Issue size
₹1,757 Cr
Face value
₹2
Registrar
MUFG Intime India Pvt.Ltd.
Issue timeline
Bidding opens
24 Aug 2026
Bidding closes
27 Aug 2026
Allotment
28 Aug 2026
Listing
01 Sept 2026
Final subscription
34,23,440
applications
₹75,628 Cr
bid value
| Category | Bid for | ₹ Cr* |
|---|---|---|
| Qualified Institutional (QIB) | 53,21,19,915 | 52,573 |
| Non-Institutional >₹10L (bNII) | 13,94,39,895 | 13,777 |
| Non-Institutional ₹2–10L (sNII) | 3,95,01,195 | 3,903 |
| Retail (RII) | 5,40,99,735 | 5,345 |
| Employees | 3,08,580 | 30 |
| Total | 76,54,69,320 | 75,628 |
Live category-wise demand from NSE only. Add each category's offered shares (from the RHP) in IPO Master to show the subscription (x) multiple.
About the company
Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products.
Issue details
Issue size
₹1,757 Cr
Fresh issue
₹150 Cr
Offer for sale
₹1,607 Cr
Industry
Pharmaceuticals
Promoter holding (pre)
34.47
Promoter holding (post)
65.53
Financials (₹ Cr)
| Metric | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Total income | 723.33 | 755.98 | 872.26 Cr |
| EBITDA | 177.04 | 206.11 | 231.97 |
| Profit after tax | 100.06 | 96.79 | 109.9 Cr |
| Net worth | 720.68 | 821.15 | 1158.64 Cr |
| Total assets | 1,294.79 | 1,579.65 | 1,780.79 |
| Total borrowing | 247.21 | 540.92 | 387.91 |
Objects of the issue
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
- General corporate purposes
Strengths
- Global leadership in corticosteroid and steroidal hormone APIs.
- Long-standing relationships with domestic and international customers.
- Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
- Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
- Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.
Risks
- Regulatory risks associated with pharmaceutical manufacturing.
- Market competition from other pharmaceutical companies.
- Dependence on a limited number of customers for a significant portion of revenue.
- Potential fluctuations in raw material prices affecting profitability.
Documents
Calculate your bid
At cut-off price ₹988
Lots
1
- Shares
- 15
- Amount
- ₹14,820
UPI mandate — funds are blocked, not debited.
- SEBI-registered broker — NSE member 90113
- Funds stay blocked in your own bank — debited only on allotment
- Apply for your whole family from one login